Dossier

Consortium ONE Study - Immunothérapie après transplantation rénale

Solid organ transplant recipients are prescribed an armamentarium of immunosuppressive treatments to prevent immunological rejection of their allograft. Clinically, these agents are associated with a myriad adverse reactions and co-morbidities for the patient, and economically, the life-long drug regimens place a substantial financial burden on the healthcare system. Therefore, a primary objective in transplantation medicine is to reduce the need for long-term use of pharmacological immunosuppression, while simultaneously protecting the allograft from host immune reactions. A means of achieving…

L’accès à la totalité de l’article est protégé




Liens d'intérêt

L’auteur n’a précisé ses éventuels liens d’intérêts.